← Leaderboards
Matthew Giacalone
Vaxiion Therapeutics, Inc.
$659,317
Attributed
$882,369
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $306.3K · FY2008–25$500K$375K$250K$125K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$882,369 · 4
By mechanism
R43$882,369 · 4
Top collaborators
- Roger Allen Sabbadini2 shared
- Steven Fiering1 shared
Most similar at Vaxiion Therapeutics, Inc.
Same institution · by research overlap
- Roger Allen Sabbadini$106,914
Others in their field
Top investigators on “Pre-Clinical”
- Leonard Freedman · Leidos Biomedical Research, Inc.$264,541,531
- Dennis R. Burton · Scripps Research Institute$257,157,696
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barton F Haynes · Duke University$186,001,832
- David Heimbrook · Leidos Biomedical Research, Inc.$151,740,590
- Reisa A. Sperling · Banner Health$137,047,788
Research focus
Pre-ClinicalSmall Business Innovation Research GrantTumorDoseImmuneCellsDesignResponseMalignant NeoplasmsMolecularToxic EffectEngineeringNeoplastic CellPatient PopulationParticlePre-Clinical ModelChromosomesIn VivoLeadBladder NeoplasmBacterial ChromosomesMalignant Neoplasm Of Urinary BladderInsightCancer Patient
Grant awards (5)
Preclinical development of VAX024 - a novel targeted combination STING agonist/oncolytic agent$306,265
R43 · FY2025 · CA · contact PI
Preclinical Evaluation of VAX014 in Combination with Immune Checkpoint Inhibitors$232,276
R43 · FY2018 · CA · contact PI
Immunotherapeutic minicells for use in intermediate and high-risk non-muscle inva$69,725
R43 · FY2014 · CA · contact PI
Immunotherapeutic minicells for use in intermediate and high-risk non-muscle inva$144,103
R43 · FY2013 · CA · contact PI
Scaling up bacterial minicell production$130,000
R43 · FY2008 · GM · contact PI